KPV

KPV is a tripeptide (lysine-proline-valine) derived from the hormone alpha-MSH, marketed for gut and skin inflammation. Its evidence comes from cell and mouse studies, including models of colitis. No published human trials were found. Since October 2026 it can be compounded on prescription in oral or topical form under an interim HHS policy, which is not FDA approval.

KPV, the anti-inflammatory tripeptide: mouse studies of colitis, no published human trials, and its status under the 2026 HHS policy.

A three-amino-acid fragment with promising mouse data and no published human trials.

Key takeaways

• Evidence is laboratory and animal only.
• A 2008 study found reduced inflammation in mouse models of colitis.
• Not FDA-approved; covered by the 2026 interim compounding policy in oral and topical forms only.
• Inflammatory bowel disease has effective, well-studied treatments; delaying them carries real risk.

Why the mouse results are not enough

Mouse colitis models are useful for understanding inflammation, but many treatments that work in them fail in people with Crohn's disease or ulcerative colitis. A positive mouse study is a reason to run a human trial, and no published trial of KPV in people was found.

If you have inflammatory bowel disease

Ulcerative colitis and Crohn's disease have treatments with large randomised trial bases, managed by a gastroenterologist. Ask about any supplement or peptide before using it, because some can interact with treatment or delay it.

Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.

Frequently asked questions

Is KPV legal?

Since 28 October 2026, a licensed pharmacist or physician in the U.S. can compound it for an individual patient with a prescription, by mouth or on the skin only, under an interim HHS policy. It is not FDA-approved, and products sold as 'research use only' are not covered.

Has KPV been tested in people?

We found no published randomised human trials. The evidence is from cells and mice.

Related on Beiing

• BPC-157 - Often sold alongside KPV in 'healing' blends.
• Peptide status tracker - Where KPV sits under the 2026 rules.
• How Beiing rates peptide evidence - The five evidence levels used in this section.
• Peptides & Human Biology - The hub for every page in this section.

Sources

1. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register document 2026-22192, docket HHS-OASH-2026-0496) - U.S. Department of Health and Human Services, via the Federal Register
2. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008 - Inflammatory Bowel Diseases (Oxford Academic)
3. PubMed: published research on the KPV tripeptide - U.S. National Library of Medicine
4. Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration

Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published August 19, 2026 · Last reviewed October 31, 2026. Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.